Skip to main content
Caplight Logo









Avilex Pharma

Avilex Pharma

Private
CopenhagenHealthcare & Life Scienceshttps://www.avilexpharma.com/

Last Round

Grant

Dec 1, 2018

Total Funding Raised

$10.14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Avilex Pharma is a biotechnology company that develops neuroprotectants intended to treat acute neurological conditions such as ischemic stroke.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

neuroprotective drugsstroke treatmentPSD-95 inhibitoracute ischemic strokeneuroprotectantstroke drugclinical-stage biotechdrug developmentpharmaceutical licensingpeptide drugsubarachnoid hemorrhagedrug discoverybiotech partnershipspostsynaptic density protein 95

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avilex Pharma Comparables

Compare Avilex Pharma with similar companies based on industry and business-model similarity.

Avilex Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NoNO Inc.
89%
Astrocyte Pharmaceuticals Inc.
82%
aptaTargets
81%

Avilex Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 1, 2018
GrantJan 28, 2015
SeedApr 15, 2013

Key People

Founding team and executive leadership

Kristian Strømgaard

Co-founder And CEO

Founding Team

Avilex Pharma Investors

Notable investors and investment history

Avilex Pharma investors
InvestorRounds
Innovation Fund DenmarkGrant
Novo HoldingsGrant, Seed
Wellcome TrustGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors grew 324% MoM.

  • May 11, 2026

    Monthly visitors grew 98% MoM, reaching 160.

Avilex Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avilex Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avilex Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range3
Year Founded2012
Last FundingDec 1, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?